Showing 4119 results for "als"

FDA Extends Tofersen Review Period to April 2023

The U.S. Food and Drug Administration (FDA) is extending by three months its review of tofersen, Biogen’s investigational treatment for forms of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene. Earlier this summer, the FDA granted the application priority review, with a decision expected no…

Biomarkers Boosted by NurOwn Regardless of Disease Severity: Data

NurOwn, Brainstorm Cell Therapeutics’ investigational cell-based therapy, leads to meaningful disease-related biomarker changes regardless of amyotrophic lateral sclerosis (ALS) severity at the start of treatment, according to data from a Phase 3 trial. Specifically, the therapy increased neuroprotection biomarker levels and anti-inflammatory molecules, and reduced those of neurodegeneration…

Funding Expands Access to SLS-005 Via Compassionate Use

Seelos Therapeutics is planning to launch an expanded access program (EAP) that gives people with amyotrophic lateral sclerosis (ALS) who are not eligible for clinical trials the opportunity to access the company’s investigational therapy SLS-005. The program will be conducted in collaboration with the Sean M. Healey &…

How I’m Finding Solace in Creative Work

On my daily walk, I take a detour from the field and into the woods because I’m on the hunt for birch bark and pine cones. It’s the season for collecting natural accents to use on my Christmas wreaths, which I’ll start making in a month. I sell them…

Cytokinetics Launches 5th Annual Patient Advocacy Grant Program

Cytokinetics has launched its fifth annual Communications Grant Program to support patient advocacy groups working with amyotrophic lateral sclerosis (ALS) and other communities. A total of five $20,000 grants will be given to winning organizations to help them improve their outreach and patient engagement. The deadline for applications…